Phase 2Recruiting
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
- Sponsor
- VA Office of Research and Development (US federal)
- Enrollment
- 78 planned
- Conditions
- Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Carcinoma
- Interventions
- Itraconazole
- Ages
- adults, older adults
- Registry
- NCT05563766
Full record on ClinicalTrials.gov
From the registry
Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers. Itraconazole, a widely used anti-fungal medication, effectively inhibits these pathways. In this multi-site phase II trial, the investigators will evaluate the effect of itraconazole as a neoadjuvant therapy added to standard of care chemoradiation or chemoimmunotherapy and surgery in the the treatment of locoregional esophageal and gastroesophageal junction cancers.
Primary outcomes
- Rate of pathological complete response with itraconazole
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered